APP 069
Alternative Names: APP-069Latest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator Aphios Corporation
- Class Antiretrovirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research HIV infections
Most Recent Events
- 01 Apr 2021 APP 069 is available for licensing as of 01 Apr 2021. https://aphios.com/products/therapeutic-products-pipeline/infectious-disease/anti-hiv-therapeutics/
- 01 Apr 2021 Aphios has multiple patents for technology (Aphios website, April 2021)
- 01 Apr 2021 Early research in HIV infections in USA (unspecified route) before April 2021 (Aphios Corporation website, April 2021)